Open AccessClinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation
Author(s) -
Xueyang Hu,
Wenjun Chen,
Xiaoqiu Li,
Chenchen Zhao,
Congjun Zhang,
Fuxing Xiong,
Hongyang Wu
Publication year - 2019
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 19
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm.2019.10.13
Subject(s) - medicine , osimertinib , adenocarcinoma , t790m , lung cancer , brain metastasis , oncology , chemotherapy , epidermal growth factor receptor , metastasis , radiation therapy , temozolomide , cancer , pathology , ros1
To find the method of therapy of leptomeningeal metastasis (LM) to non-small cell lung cancer (NSCLC) patient with EGFR mutation (EGFR+) but without T790M mutation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom